



Nebraska Medicaid DUR Board Meeting

Tuesday October 28th, 2025

DRAFT pending approval at the next meeting

DUR Board Members in attendance: Marin Broucek, M.D., Matt Titchener R.P., Charlie Moore, R.P. Excused absence: David Randolph, R. P., Jaci Timmons, M. D.

Nebraska Medicaid and LTC attendees in attendance: Lee Stutzman, R.P., Pharmacy Director, Leah Spencer, R.N. Program Specialist, Dianne Garside, R.P., Spencer Moore, R.P.

Contracted attendees: Jamie Benson, R.P., Nebraska Total Care; Michael Labadie, R.P., Molina Healthcare, Bernadette Ueda, R.P., United Health Care, Shaleigh Hammons, Account Executive, Prime Therapeutics, Sandy Pranger, R.P., Sr. Director Clinical Account Services Prime Therapeutics

Public Attendees in attendance: Suzanne Hansen, Gilead; Jodi Fuehrer, Renewal Health Outreach; Jon Freeland, Novo Nordisk; Randy Roth, Merck; Deb Hartle, Walgreens; Ginger Papesh, Novo Nordisk; Tina Hartman, Arcutis; Shelly Nickerson, Neurocrine; Justin Springfield, Gilead; Sherry Betthauser, Jazz

I. Opening and Introductions

Lee Stutzman called the meeting to order at 6:30 PM. The meeting was held at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE. A copy of the open meetings act was available. Stutzman introduced the new Pharmacy Director for Molina Healthcare of Nebraska, Michael Labadie.

II. Declaration of any Conflict of Interest or changes

No changes in conflict of interest were declared.

III. Agenda approval

The agenda for the meeting was approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

IV. Review and Approval of Minutes from previous Board meeting Sept 9th, 2025

The meeting minutes were approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

V. Update on Recommendations from Previous Meeting

Stutzman announced that the age limit on Naltrexone tablets will be lowered from age 18 to 15 years old.

VI. Retrospective DUR

Old Business

Spencer Moore presented SUPPORT Act data. Charlie Moore made a motion to review the SUPPORT Act data with the addition of an aggregated view of all 4 therapeutic classes with concomitant utilization among unique members. Motion passed was approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

Further data on Buprenorphine utilization was presented, showing an increase in the number of prescribers from previous data and noting that the State had sent SUD/buprenorphine education to prescribers in May of 2025.

New Business

Spencer Moore presented data on Hepatitis C PDL compliance. No questions or comments from the Board.

VII.Prospective DUR

Old Business

Dianne Garside presented the Buprenorphine for Opioid Dependence Treatment PA criteria form for annual review. No changes were recommended. A motion to approve the form as written was made by Marin Broucek and was approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

Dianne Garside presented the Insulin-Like Growth Factor PA criteria form for annual review. No changes were recommended. A motion to approve the form as written was made by Charlie Moore and was approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

New Business – None

VIII.Special Requests from the Department - none

IX.Future Meeting Dates

January 13th, 2026, May 12th, 2026, August 18th, 2026, October or November meeting to be determined

X.Concerns and Comments from the DUR Board

Charlie Moore notes continued difficulties with pricing and reimbursement from the managed care organizations.

XI.Concerns and Comments from the DUR Director – none

XII.Concerns and Comments from the State DHHS Representatives– none

XIII.Concerns and Comments from the MCO Representatives – none

XIV.Concerns and Comments from the Public Attendees – none

XV.Adjournment

Motion to adjourn the meeting was approved at 7:04 PM. No objections were made from the Board.